A Phase 1 Study of GRN163L (Imetelstat) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia That is in Second or Greater Relapse or That is Refractory to Relapse Therapy; Myelodysplastic Syndrome or Juvenile Myelomonocytic Leukemia in First or Greater Relapse or is Refractory to Relapse Therapy

This phase I trial tests the safety, side effects, and best dose of imetelstat in combination with fludarabine and cytarabine in treating patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or juvenile myelomonocytic leukemia (JMML) that has not responded to previous treatment (refractory) or that has come back after a period of improvement (recurrent). Imetelstat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as fludarabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving imetelstat in combination with fludarabine and cytarabine may work better in treating patients with refractory or recurrent AML, MDS, and JMML.

开始日期2025-02-04

申办/合作机构

The Children's Oncology Group Foundation, Inc.

[+2]

NCT05761171

/ Recruiting临床2期IIT

A Phase 2 Study of Revumenib (SNDX-5613) in Combination With Chemotherapy for Patients With Relapsed or Refractory KMT2A-Rearranged Infant Leukemia

This phase II trial tests the safety and best dose of revumenib in combination with chemotherapy, and evaluates whether this treatment improves the outcome in infants and young children who have leukemia that has come back (relapsed) or does not respond to treatment (refractory) and is associated with a KMT2A (MLL) gene rearrangement (KMT2A-R). Leukemia is a cancer of the white blood cells, where too many underdeveloped (abnormal) white blood cells, called "blasts", are found in the bone marrow, which is the soft, spongy center of the bones that produces the three major blood cells: white blood cells to fight infection; red blood cells that carry oxygen; and platelets that help blood clot and stop bleeding. The blasts crowd out the normal blood cells in the bone marrow and spread to the blood. They can also spread to the brain, spinal cord, and/or other organs of the body. The leukemia cells of some children have a genetic change in which a gene (KMT2A) is broken and combined with other genes that typically do not interact with one another; this is called "rearranged". This genetic rearrangement alters how other genes are turned on or off in the cell, turning on genes that drive the development of leukemia. Patients with KMT2A rearrangement have higher risk for cancer coming back after treatment. Revumenib is an oral medicine that directly targets the changes that occur in a cell with a KMT2A rearrangement and has been shown to specifically kill these leukemia cells in preclinical laboratory settings and in animals. Drugs used in chemotherapy, such as vincristine, prednisone, asparaginase, fludarabine and cytarabine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial is being done to find out if the combination of revumenib and chemotherapy would be safe and/or effective in treating infants and young children with relapsed or refractory KMT2A-R leukemia.

开始日期2024-01-08

申办/合作机构

The Children's Oncology Group Foundation, Inc.

NCT05320380

/ Withdrawn临床1/2期IIT

A PedAL/EuPAL Phase 1/2 Trial of IMGN632 in Pediatric Patients With Relapsed or Refractory Leukemia

This phase I/II trial finds the highest safe dose of IMGN632 that can be given with other chemotherapy without causing severe side effects, studies what kind of side effects IMGN632 may cause, and determines whether IMGN632 is a beneficial treatment for leukemia in children that has come back after treatment or is difficult to treat. IMGN632 is a monoclonal antibody linked to a chemotherapy drug. IMGN632 is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD123 receptors, and delivers the chemotherapy drug to kill them. Giving IMGN632 with other chemotherapy may cause the leukemia to stop growing or to shrink for a period of time.

开始日期2023-08-01

申办/合作机构

The Children's Oncology Group Foundation, Inc.

[+2]

100 项与氢化可的松琥珀酸钠相关的临床结果

登录后查看更多信息

100 项与氢化可的松琥珀酸钠相关的转化医学

登录后查看更多信息

100 项与氢化可的松琥珀酸钠相关的专利（医药）

登录后查看更多信息

1,706

项与氢化可的松琥珀酸钠相关的文献（医药）

2024-10-10·Cureus Journal of Medical Science

Delayed Emergence of Isolated Secondary Adrenal Insufficiency: A Case Report

Article

作者: Ovalles Lacruz, Alexa ; Mesa, Natalie ; Blanco Guertin, Angela ; Vassil, Steven T ; Sharma, Deepa

Secondary adrenal insufficiency (SAI) is a rare condition caused by adrenocorticotropic hormone (ACTH) deficiency, which disrupts ACTH secretion by the pituitary gland and can lead to chronic hyponatremia. However, idiopathic delayed onset of isolated adrenal insufficiency without triggering factors is an unusual finding and poses a challenging diagnosis. We present the case of an 80-year-old woman with hypothyroidism, hypertension, previous tobacco use, and squamous cell carcinoma of the ankle who presented with weakness and fatigue. Blood work showed hyponatremia (126 mmol/L), nonfasting blood glucose of 139 mg/dL, and elevated erythrocyte sedimentation rate (ESR, 83 mm/hr). Initial treatment included urea administration and water restriction. Initial imagining included a CT of the chest which revealed mediastinal lymphadenopathy, leading to suspicion of the syndrome of inappropriate antidiuretic hormone (SIADH) from malignancy. Despite increasing urea and adding NaHCO₃, sodium levels dropped further. Tolvaptan was administered but showed no improvement. Endocrinology recommended hydrocortisone sodium succinate (Solu-Cortef) leading to sodium normalization and symptom resolution. A full pituitary workup revealed low dehydroepiandrosterone sulfate (DHEA-S), and abdominal CT showed atrophic adrenal glands. MRI of the sella turcica was normal with no evidence of a mass. The patient was discharged on an oral course of Solu-Cortef with stable sodium levels (139 mEq/L). This is among the first reported cases of unprovoked isolated adrenal insufficiency with abnormal cortisol, ACTH, DHEA-S levels, and normal renin and aldosterone levels. Diagnosis is often delayed due to nonspecific symptoms. Once identified, corticosteroid replacement therapy is the gold standard for management.

2024-09-01·STEROIDS

Biotransformation of hydrocortisone succinate with whole cell cultures of Monascus purpureus and Cunninghamella echinulata

Article

作者: Aziz, Zainab ; Rashid Khan, Afsana ; Sheema ; Iqbal, Amir ; Rahman Khan, Abdur ; Zafar, Salman

Hydrocortisone succinate (1) is a synthetic anti-inflammatory drug and key intermediate in the synthesis of other steroidal drugs. This work is based on the fungal biotransformation of 1, using Monascus purpureus and Cunninghamella echinulata strains. Comopound 1 was transformed into four metabolites, identified as hydrocortisone (2), 11β-hydroxyandrost-4-en-3,17-dione (3), Δ¹-cortienic acid (4), and hydrocortisone-17-succinate (5), obtained through side chain cleavage, hydrolysis, dehydrogenation, and oxidation reactions. These compounds have previously been synthesized either chemically or enzymatically from different precursors. Though this is not the first report on the biotransformation of 1, but it obviously is a first, where the biotransformed products of compound 1 have been characterized structurally with the help of modern spectroscopic techniques. It is noteworthy that these products have already shown biological potential, however a more thorough investigation of the anti-inflammatory properties of these metabolites would be of high value. These results not only emphasize upon the immense potential of biotransformation in catalysis of reactions, otherwise not-achievable chemically, but also holds promise for the development of novel anti-inflammatory compounds.

2024-08-01·INTERNATIONAL JOURNAL OF UROLOGY

J‐AVENUE: A retrospective, real‐world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first‐line maintenance therapy in Japan

Article

作者: Kobayashi, Mizuki ; Kitamura, Hiroshi ; Nakayama, Masashi ; Nishiyama, Naotaka ; Ito, Takayuki ; Miyake, Hideaki ; Kikuchi, Eiji ; Nakatsu, Hiroomi ; Kobayashi, Takashi ; Fujita, Kazutoshi ; Hayakawa, Nozomi ; Shimoyama, Hideaki ; Kitagawa, Chiyoe ; Uno, Masahiro ; Sano, Takeshi ; Nishihara, Kiyoaki ; Nakamura, Motonobu ; Yamada, Takeshi ; Kajita, Masahiro ; Fujimoto, Kiyohide

Objectives:

The JAVELIN Bladder 100 phase 3 trial showed that avelumab first‐line maintenance + best supportive care significantly prolonged overall survival and progression‐free survival versus best supportive care alone in patients with advanced urothelial carcinoma who were progression‐free following first‐line platinum‐based chemotherapy. We report findings from J‐AVENUE (NCT05431777), a real‐world study of avelumab first‐line maintenance therapy in Japan.

Methods:

Medical charts of patients with advanced urothelial carcinoma without disease progression following first‐line platinum‐based chemotherapy, who received avelumab maintenance between February and November 2021, were reviewed. Patients were followed until June 2022. The primary endpoint was patient characteristics; secondary endpoints included time to treatment failure and progression‐free survival.

Results:

In 79 patients analyzed, median age was 72 years (range, 44–86). Primary tumor site was upper tract in 45.6% and bladder in 54.4%. The most common first‐line chemotherapy regimen was cisplatin + gemcitabine (63.3%). Median number of chemotherapy cycles received was four. Best response to chemotherapy was complete response in 10.1%, partial response in 58.2%, and stable disease in 31.6%. Median treatment‐free interval before avelumab was 4.9 weeks. With avelumab first‐line maintenance therapy, the disease control rate was 58.2%, median time to treatment failure was 4.6 months (95% CI, 3.3–6.4), and median progression‐free survival was 6.1 months (95% CI, 3.6–9.7).

Conclusions:

Findings from J‐AVENUE show the effectiveness of avelumab first‐line maintenance in patients with advanced urothelial carcinoma in Japan in clinical practice, with similar progression‐free survival to JAVELIN Bladder 100 and previous real‐world studies, supporting its use as a standard of care.

项与氢化可的松琥珀酸钠相关的新闻（医药）

2025-03-23

·信狐药迅

江苏柯菲平改良新醋酸沃诺拉赞注射液提交上市申请|新受理（3.17-3.23）

本周药品注册受理数据，分门别类呈现，一目了然。(3.17-3.23）新药上市申请药品名称企业注册分类受理号醋酸沃诺拉赞注射液江苏柯菲平医药股份有限公司2.1;2.2;2.4CXHS2500023瑞加诺生注射液南京瑞克卫生物医药有限公司2.4CXHS2500024 新药临床申请药品名称企业注册分类受理号ICP-248片北京诺诚健华医药科技有限公司1CXHL2500308ICP-248片北京诺诚健华医药科技有限公司1CXHL2500307NH104片江苏恩华药业股份有限公司1CXHL2500312NH104片江苏恩华药业股份有限公司1CXHL2500311AP303片礼邦药业(上海)有限公司1CXHL2500306AP303片礼邦药业(上海)有限公司1CXHL2500305AP303片礼邦药业(上海)有限公司1CXHL2500304AP303片礼邦药业(上海)有限公司1CXHL2500303AP303片礼邦药业(上海)有限公司1CXHL2500302苹果酸法米替尼胶囊江苏恒瑞医药股份有限公司1CXHL2500298RFUS-949片宜昌人福药业有限责任公司1CXHL2500297RFUS-949片宜昌人福药业有限责任公司1CXHL2500296GST-HG131片福建广生中霖生物科技有限公司1CXHL2500295GST-HG131片福建广生中霖生物科技有限公司1CXHL2500294奈瑞可韦片福建广生中霖生物科技有限公司1CXHL2500293奈瑞可韦片福建广生中霖生物科技有限公司1CXHL2500292TP1001 片生元泽通(上海)医药有限公司1CXHL2500300TP1001 片生元泽通(上海)医药有限公司1CXHL2500299布瑞哌唑口溶膜上海现代制药股份有限公司2.2CXHL2500310布瑞哌唑口溶膜上海现代制药股份有限公司2.2CXHL2500309NS1009新领医药(中山)有限公司2.2CXHL2500301CMCY2501片杭州中美华东制药有限公司2.4CXHL2500314ZHCX002九华华源药业股份有限公司2.4CXHL2500313吸附组分无细胞百白破(减剂量)联合疫苗中国医学科学院医学生物学研究所2.5CXSL2500229吸附组分无细胞百白破(减剂量)联合疫苗中国医学科学院医学生物学研究所2.5CXSL2500228流感病毒裂解疫苗(BK-01佐剂)长春百克生物科技股份公司3.2CXSL2500240流感病毒裂解疫苗(BK-01佐剂)长春百克生物科技股份公司3.2CXSL2500239GenSci134注射液长春金赛药业有限责任公司1CXSL2500238GenSci134注射液长春金赛药业有限责任公司1CXSL2500237BT02单克隆抗体注射液上海柏全生物科技有限公司1CXSL2500236VPD/FC01002 注射液微能生命科技集团有限公司1CXSL2500234SSS55注射液沈阳三生制药有限责任公司1CXSL2500235GB18注射液深圳科兴药业有限公司1CXSL2500226IBI363信达生物制药(苏州)有限公司1CXSL2500233IBI363信达生物制药(苏州)有限公司1CXSL2500232注射用SHR-A1811苏州盛迪亚生物医药有限公司1CXSL2500230阿得贝利单抗注射液上海盛迪医药有限公司2.2CXSL2500231 仿制药申请药品名称企业注册分类受理号秋水仙碱片一加药业(湖北)有限公司3CYHS2501148重酒石酸去甲肾上腺素注射液上海炫鑫医药科技有限公司3CYHS2501147乙酰唑胺片上海理想制药有限公司3CYHS2501142碘[131I]化钠口服溶液成都欣科医药有限公司3CYHS2501145呋塞米注射液华夏生生药业(北京)有限公司3CYHS2501124阿仑膦酸钠口服溶液黑龙江中桂制药有限公司3CYHS2501120福多司坦片湖北远大永晟药业有限公司3CYHS2501117盐酸溴己新注射液多多药业有限公司3CYHS2501114维生素B12注射液海南全星制药有限公司3CYHS2501128盐酸甲氧氯普胺注射液湖北天圣药业有限公司3CYHS2501127碘[131I]化钠口服溶液成都纽瑞特医疗科技股份有限公司3CYHS2501125盐酸布比卡因注射液河南普瑞药业有限公司3CYHS2501116盐酸布比卡因注射液河南普瑞药业有限公司3CYHS2501115盐酸溴己新口服溶液江苏欧歌制药有限公司3CYHS2501110间苯三酚口崩片四川海梦智森生物制药有限公司3CYHS2501105左羟丙哌嗪口服溶液江苏润恒制药有限公司3CYHS2501104加替沙星滴眼液合肥诺瑞特制药有限公司3CYHS2501102维生素B6注射液上海禾丰制药有限公司3CYHS2501112酒石酸阿福特罗吸入溶液正大天晴药业集团股份有限公司3CYHS2501111注射用氢化可的松琥珀酸钠河南利华制药有限公司3CYHS2501100注射用氢化可的松琥珀酸钠河南利华制药有限公司3CYHS2501099盐酸普罗帕酮注射液安徽长江药业有限公司3CYHS2501097硝普钠注射液成都欣捷高新技术开发股份有限公司3CYHS2501096硝普钠注射液成都欣捷高新技术开发股份有限公司3CYHS2501095注射用盐酸多西环素海南倍特药业有限公司3CYHS2501092盐酸拉贝洛尔注射液九华华源药业(桂林)有限公司3CYHS2501090盐酸拉贝洛尔注射液九华华源药业(桂林)有限公司3CYHS2501089盐酸利多卡因注射液河南普瑞药业有限公司3CYHS2501088盐酸利多卡因注射液河南普瑞药业有限公司3CYHS2501087双氯芬酸二乙胺乳胶剂海南紫程众投生物科技有限公司4CYHS2501153双氯芬酸二乙胺乳胶剂海南紫程众投生物科技有限公司4CYHS2501152来特莫韦注射液安徽省先锋制药有限公司4CYHS2501151枸橼酸西地那非口腔崩解片西施兰(南阳)药业股份有限公司4CYHS2501150甲磺酸酚妥拉明注射液成都倍特药业股份有限公司4CYHS2501149盐酸西替利嗪滴剂江苏联环药业股份有限公司4CYHS2501144地夸磷索钠滴眼液杭州民生药物研究院有限公司4CYHS2501143阿奇霉素片辰欣药业股份有限公司4CYHS2501141莫匹罗星软膏湖北午时药业股份有限公司4CYHS2501140利多卡因凝胶贴膏湖南华纳大药厂股份有限公司4CYHS2501139莫匹罗星软膏湖北午时药业股份有限公司4CYHS2501138莫匹罗星软膏湖北午时药业股份有限公司4CYHS2501137碘普罗胺注射液重庆药友制药有限责任公司4CYHS2501136碘普罗胺注射液重庆药友制药有限责任公司4CYHS2501135盐酸贝尼地平片福建东瑞制药有限公司4CYHS2501134盐酸贝尼地平片福建东瑞制药有限公司4CYHS2501133氧榆林市北方化工有限公司4CYHS2501132瑞舒伐他汀依折麦布片(Ⅰ)北京伟林恒昌医药科技有限公司4CYHS2501131卡格列净片江苏华鑫制药有限公司4CYHS2501130卡格列净片江苏华鑫制药有限公司4CYHS2501129培哚普利氨氯地平片(I)南京海纳制药有限公司4CYHS2501146贝美前列素滴眼液海南斯达制药有限公司4CYHS2501123氧(气态)陕西省汉中市汽车运输集团有限公司乙炔气厂4CYHS2501122骨化三醇软胶囊珠海健福制药有限公司4CYHS2501121洛索洛芬钠贴剂湖南华纳大药厂股份有限公司4CYHS2501119洛索洛芬钠贴剂湖南华纳大药厂股份有限公司4CYHS2501118布地奈德肠溶胶囊石药集团中诺药业(石家庄)有限公司4CYHS2501113氧(气态)镇安县康欣气体有限公司4CYHS2501126富马酸伏诺拉生片山西宝泰药业有限责任公司4CYHS2501109富马酸伏诺拉生片山西宝泰药业有限责任公司4CYHS2501108碳酸司维拉姆片仁合益康集团有限公司4CYHS2501107盐酸曲唑酮缓释片山东京卫制药有限公司4CYHS2501106黄体酮软胶囊苏州朗科生物技术股份有限公司4CYHS2501103硫酸氨基葡萄糖胶囊瀚玛斯(山西)医药科技有限公司4CYHS2501098艾拉莫德片安徽艾立德制药有限公司4CYHS2501094诺西那生钠注射液成都国为生物医药有限公司4CYHS2501093钆布醇注射液石家庄四药有限公司4CYHS2501091盐酸托莫西汀口服溶液山东新时代药业有限公司4CYHS2501101吡美莫司乳膏江苏盈科生物制药有限公司4CYHS2501086流感病毒裂解疫苗成大生物(本溪)有限公司3.3CXSS2500037酮洛芬凝胶贴膏北京阳光诺和药物研究股份有限公司3CYHL2500064艾拉戈克钠片东莞松山湖美健生物技术有限公司3CYHL2500063艾拉戈克钠片东莞松山湖美健生物技术有限公司3CYHL2500062 进口申请药品名称企业注册分类受理号利妥昔单抗注射液Roche Pharma(Schweiz)AG2.2JXSS2500036利妥昔单抗注射液Roche Pharma(Schweiz)AG2.2JXSS2500035利妥昔单抗注射液Roche Pharma(Schweiz)AG2.2JXSS2500034利妥昔单抗注射液Roche Pharma(Schweiz)AG2.2JXSS2500033利妥昔单抗注射液Roche Pharma(Schweiz)AG2.2JXSS2500032利妥昔单抗注射液Roche Pharma(Schweiz)AG2.2JXSS2500031利妥昔单抗注射液Roche Pharma(Schweiz)AG2.2JXSS2500030利妥昔单抗注射液Roche Pharma(Schweiz)AG2.2JXSS2500029度伐利尤单抗注射液AstraZeneca UK Limited3.1JXSS2500028度伐利尤单抗注射液AstraZeneca UK Limited3.1JXSS2500027阿帕他胺片Aizant Drug Research Solutions Private Limited.5.2JYHS2500015MK-1084片Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.1JXHL2500051MK-1084片Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.1JXHL2500050VSA001注射液Arrowhead Pharmaceuticals, Inc.1JXHL2500048[225Ac]Ac-PSMA-617注射液Novartis Pharma AG1JXHL2500047地非法林注射液Vifor Fresenius Medical Care Renal Pharma Ltd.2.4JXHL2500049用于制备放射性药物镓(68Ga)gozetotide注射液的药盒Novartis Europharm Limited5.1JXHL2500046 中药相关申请药品名称企业注册分类受理号天苓止眩片湖南中医药大学1.1CXZL2500019松龄血脉康胶囊成都康弘制药有限公司2.3CXZL2500018夏枯草口服液江西和盈药业有限公司4CYZS2500004 注：绿色字体部分为潜在首仿品种；不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

疫苗申请上市

2025-01-09

·FierceBiotech

Lilly crafts deal for up to 5 new ALS antibodies with UK biotech Alchemab

Lilly\'s deal comes as other industry players struggle to win in the clinic with their own ALS candidates.\n It’s been a rough month for several clinical amyotrophic lateral sclerosis (ALS) candidates, but that’s not stopping Eli Lilly from pursuing new drugs of its own for the devastating neurological disease. The Big Pharma has inked a deal with British biotech Alchemab Therapeutics to develop new antibodies for ALS.Under the terms of the deal, Alchemab and Lilly will work together on up to five new antibodies, according to a Jan. 9 release. Alchemab will receive an undisclosed upfront payment and can also earn payments based on hitting discovery, development and commercialization milestones, as well as royalties. Alchemab’s platform analyzes ALS patients with unusually slow disease progression to identify potential antibodies they may possess that contribute to the slower decline, the company said in the release.\"We have shown that our novel, differentiated antibody discovery platform can lead to insights into how an individual\'s immune response can generate potent, selective and unique antibodies with therapeutic potential,” Alchemab CEO Jane Osbourn, Ph.D., said in the release. “Alchemab\'s platform yields both novel targets and potential therapies in one process.”Earlier this week, investigational ALS treatments from AbbVie-Calico and Denali both failed to slow disease progression in phase 2/3 trials. Those drugs target eukaryotic translation initiation factor 2B (eIF2B), an enzyme that plays a key role in the cellular stress response.And in December, Corcept’s cortisol modulator was also unable to slow ALS progression in phase 2, while also being linked to gastrointestinal upset.

引进/卖出

2024-12-31

·PipelineReview

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism

REDWOOD CITY, CA, USA I December 30, 2024 I Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, has submitted a new drug application (NDA) to the U.S. Food and Drug Administration for its proprietary, selective cortisol modulator, relacorilant, to treat patients with endogenous hypercortisolism (Cushing’s syndrome). Corcept’s NDA is based on positive results from the pivotal GRACE trial and confirmatory evidence from the Phase 3 GRADIENT and long-term extension studies and a Phase 2 study in hypercortisolism. Patients in these studies who received relacorilant experienced improvements in a wide array of hypercortisolism’s signs and symptoms, with an acceptable safety burden. Notably, there were no instances of drug-induced adrenal insufficiency, hypokalemia or QT prolongation – serious adverse events that can arise in patients taking currently approved medications – and no adverse events associated with activity at the progesterone receptor, such as endometrial thickening or vaginal bleeding. “Relacorilant’s combination of efficacy and safety give it the potential to become the standard of care for the medical treatment of patients with hypercortisolism,” said Joseph Belanoff, MD, Corcept’s Chief Executive Officer. “Our commitment to the health of patients with hypercortisolism is unwavering. We are optimistic that relacorilant will be of great benefit to them.” About Relacorilant Relacorilant is a selective cortisol modulator that binds to the glucocorticoid receptor but not to the body’s other hormone receptors. Corcept is studying relacorilant in a variety of serious disorders in addition to endogenous hypercortisolism (Cushing’s syndrome), including ovarian, adrenal and prostate cancer. Relacorilant is proprietary to Corcept and is protected by composition of matter, method of use and other patents. Relacorilant has orphan drug designation in the United States and the European Union for the treatment of Cushing’s syndrome. About Hypercortisolism (Cushing’s Syndrome) Hypercortisolism is caused by excessive activity of the hormone cortisol. Symptoms vary, but most patients experience one or more of the following manifestations: hypertension, central obesity, elevated blood sugar and difficult-to-control type 2 diabetes, severe fatigue and weak muscles. Irritability, anxiety, depression and cognitive disturbances are common. Hypercortisolism can affect every organ system and can be lethal if not treated effectively. About Corcept Therapeutics For over 25 years, Corcept’s focus on cortisol modulation and its potential to treat patients with a wide variety of serious disorders has led to the discovery of more than 1,000 proprietary selective cortisol modulators. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym ® , the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California. For more information, visit Corcept.com. SOURCE: Corcept Therapeutics

临床结果孤儿药申请上市上市批准临床2期

100 项与氢化可的松琥珀酸钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00978	氢化可的松琥珀酸钠	D07AA02 A01AC03 S02BA01	DB14545

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
哮喘	日本	Pfizer Japan, Inc.	1958-04-23
创伤性休克	日本	Pfizer Japan, Inc.	1958-04-23
沃-弗综合征	日本	Pfizer Japan, Inc.	1958-04-23
过敏	美国	Pharmacia & Upjohn, Inc.	1955-04-27
内分泌系统疾病	美国	Pharmacia & Upjohn, Inc.	1955-04-27
眼部疾病	美国	Pharmacia & Upjohn, Inc.	1955-04-27
血液疾病	美国	Pharmacia & Upjohn, Inc.	1955-04-27
肾脏疾病	美国	Pharmacia & Upjohn, Inc.	1955-04-27
肿瘤	美国	Pharmacia & Upjohn, Inc.	1955-04-27
呼吸系统疾病	美国	Pharmacia & Upjohn, Inc.	1955-04-27
风湿性疾病	美国	Pharmacia & Upjohn, Inc.	1955-04-27
皮肤疾病	美国	Pharmacia & Upjohn, Inc.	1955-04-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


UEGW2018	N/A	病理性缩窄	-	Oral mixture of hydrocortisone sodium succinate and aluminum phosphate gel	壓醖糧範蓋蓋範鏇壓積(簾窪選蓋憲淵網膚鏇糧) = 網膚窪壓衊鑰廠鏇顧繭構鹹壓糧鹹鑰糧遞糧簾 (鹹鹽願襯蓋壓築蓋繭遞, 1 ~ 1.8) 更多	-	2018-10-01
				hydrocortisone sodium succinate (EBD alone)	壓醖糧範蓋蓋範鏇壓積(簾窪選蓋憲淵網膚鏇糧) = 鹽選蓋顧醖選壓選觸獵構鹹壓糧鹹鑰糧遞糧簾 (鹹鹽願襯蓋壓築蓋繭遞, 1 ~ 2.5) 更多
UEGW2018	N/A	食管癌	-	Endoscopic intralesional steroid injection + systemic steroid treatment	範糧醖積鑰鬱廠淵遞齋(觸窪窪淵窪鹽製鏇夢衊) = 餘觸憲觸窪獵積鹹構觸襯選醖衊積醖遞艱積簾 (築壓網鬱蓋鬱顧鑰製築, 0 ~ 1) 更多	-	2018-10-01
				Oral mixture of hydrocortisone sodium succinate and aluminum phosphate gel	積獵簾鹽遞衊淵醖構鏇(製網製製膚衊積衊鏇鹽) = 鬱鏇積襯糧獵繭窪衊衊窪齋鏇艱艱鹹鬱鏇鹽顧 (構獵觸齋觸觸範繭網遞 )
UEGW2017	N/A	食管癌	-	Systemic steroid treatment (ST)	築壓襯網積鬱顧齋選膚(鏇遞獵糧積襯繭膚餘壓) = 襯鬱鬱襯獵壓選衊觸範壓範憲繭鏇蓋蓋夢醖鑰 (繭膚淵齋糧觸廠膚鑰範 ) 更多	-	2017-10-01
				Endoscopic intralesional steroid (triamcinolone acetonide 80 mg) injection accompanied with systemic steroid treatment (IT + ST)	築壓襯網積鬱顧齋選膚(鏇遞獵糧積襯繭膚餘壓) = 鑰艱衊憲鹹襯鬱選選餘壓範憲繭鏇蓋蓋夢醖鑰 (繭膚淵齋糧觸廠膚鑰範 ) 更多